Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting
| KPRX Stock | USD 3.26 0.31 8.68% |
Slightly above 62% of Kiora Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Kiora Pharmaceuticals suggests that many traders are alarmed. Kiora Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Kiora Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Kiora |
Encinitas, California-- - Kiora Pharmaceuticals, Inc. , today announced three abstract acceptances for oral and poster presentation at the 2023 Association for Research in Vision and Ophthalmology meeting in New Orleans, La., April 23-27, 2023. Further results from each of these three studies will be reported at the conference.A presentation will report interim results on safety, tolerability and efficacy from the A
Read at finance.yahoo.com
 |
Kiora Pharmaceuticals Fundamental Analysis
We analyze Kiora Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiora Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiora Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Kiora Pharmaceuticals is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Kiora Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kiora Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Kiora Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiora Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Kiora Pharmaceuticals Related Equities
| BDRX | Biodexa Pharmaceticals | 14.00 | ||||
| QNRX | Quoin Pharmaceuticals | 1.69 | ||||
| PALI | Palisade Bio | 1.65 | ||||
| UNCY | Unicycive Therapeutics | 1.47 | ||||
| REVB | Revelation Biosciences | 1.33 | ||||
| ALLR | Allarity Therapeutics | 0.90 | ||||
| CDIO | Cardio Diagnostics | 3.23 | ||||
| VRAX | Virax Biolabs | 4.83 |
Additional Tools for Kiora Stock Analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.